| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| 21 | 24 | 27 | 26 | |
Growth YoY Revenue Growth YoY% | 29.1 | 5.0 | ||
| 16 | 18 | 20 | 18 | |
| 5 | 7 | 7 | 8 | |
OPM OPM% | 23.1 | 27.0 | 27.0 | 29.9 |
| 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 1 | 1 |
PBT PBTCr | 4 | 6 | 7 | 7 |
| 1 | 2 | 2 | 2 | |
| 3 | 4 | 5 | 4 | |
Growth YoY PAT Growth YoY% | 60.4 | -1.2 | ||
NPM NPM% | 13.6 | 17.4 | 16.9 | 16.4 |
| 0.0 | 0.0 | 0.0 | 0.0 |
| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| 21 | 24 | 27 | 26 | |
Growth YoY Revenue Growth YoY% | 29.1 | 5.0 | ||
| 16 | 18 | 20 | 18 | |
| 5 | 7 | 7 | 8 | |
OPM OPM% | 23.1 | 27.0 | 27.0 | 29.9 |
| 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 1 | 1 |
PBT PBTCr | 4 | 6 | 7 | 7 |
| 1 | 2 | 2 | 2 | |
| 3 | 4 | 5 | 4 | |
Growth YoY PAT Growth YoY% | 60.4 | -1.2 | ||
NPM NPM% | 13.6 | 17.4 | 16.9 | 16.4 |
| 0.0 | 0.0 | 0.0 | 0.0 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
Revenue RevenueCr | 24 | 45 | 53 |
Growth Revenue Growth% | 88.8 | 16.1 | |
| 20 | 34 | 38 | |
| 4 | 11 | 15 | |
OPM OPM% | 17.3 | 25.4 | 28.4 |
| 0 | 1 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 1 | 2 |
Depreciation DepreciationCr | 1 | 1 | 1 |
PBT PBTCr | 3 | 10 | 12 |
| 1 | 3 | 4 | |
PAT PATCr | 2 | 7 | 9 |
Growth PAT Growth% | 228.9 | 23.3 | |
NPM NPM% | 9.0 | 15.7 | 16.7 |
| 6.6 | 18.7 | 21.7 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
Revenue RevenueCr | 24 | 45 | 53 |
Growth Revenue Growth% | 88.8 | 16.1 | |
| 20 | 34 | 38 | |
| 4 | 11 | 15 | |
OPM OPM% | 17.3 | 25.4 | 28.4 |
| 0 | 1 | 0 | |
Interest Expense Interest ExpenseCr | 1 | 1 | 2 |
Depreciation DepreciationCr | 1 | 1 | 1 |
PBT PBTCr | 3 | 10 | 12 |
| 1 | 3 | 4 | |
PAT PATCr | 2 | 7 | 9 |
Growth PAT Growth% | 228.9 | 23.3 | |
NPM NPM% | 9.0 | 15.7 | 16.7 |
| 6.6 | 18.7 | 21.7 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 3 | 4 | 4 |
Reserves ReservesCr | 3 | 19 | 27 |
| 21 | 24 | 30 | |
| 8 | 10 | 14 | |
| 35 | 56 | 75 | |
| 23 | 37 | 43 | |
| 12 | 19 | 31 | |
| 35 | 56 | 75 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 3 | 4 | 4 |
Reserves ReservesCr | 3 | 19 | 27 |
| 21 | 24 | 30 | |
| 8 | 10 | 14 | |
| 35 | 56 | 75 | |
| 23 | 37 | 43 | |
| 12 | 19 | 31 | |
| 35 | 56 | 75 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| 1 | 3 | 6 | |
| -4 | -10 | -13 | |
| 3 | 10 | 5 | |
Net Cash Flow Net Cash FlowCr | 0 | 4 | -2 |
Free Cash Flow Free Cash FlowCr | -3 | -6 | -7 |
CFO To PAT CFO To PAT% | 47.1 | 47.8 | 67.5 |
CFO To EBITDA CFO To EBITDA% | 24.5 | 29.6 | 39.5 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| 1 | 3 | 6 | |
| -4 | -10 | -13 | |
| 3 | 10 | 5 | |
Net Cash Flow Net Cash FlowCr | 0 | 4 | -2 |
Free Cash Flow Free Cash FlowCr | -3 | -6 | -7 |
CFO To PAT CFO To PAT% | 47.1 | 47.8 | 67.5 |
CFO To EBITDA CFO To EBITDA% | 24.5 | 29.6 | 39.5 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 181 | |||
Price To Earnings Price To Earnings | 21.2 | |||
Price To Sales Price To Sales | 3.5 | |||
Price To Book Price To Book | 2.0 | |||
EV To EBITDA EV To EBITDA | 14.3 | |||
GPM GPM% | 34.3 | 39.7 | 44.6 | 44.6 |
OPM OPM% | 17.3 | 25.4 | 28.4 | 28.4 |
NPM NPM% | 9.0 | 15.7 | 16.7 | 16.7 |
ROCE ROCE% | 18.4 | 25.0 | 23.2 | 23.2 |
ROE ROE% | 34.7 | 31.3 | 27.9 | 27.9 |
ROA ROA% | 6.2 | 12.6 | 11.7 | 11.7 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|
Market Cap Market CapitalizationCr | 181 | |||
Price To Earnings Price To Earnings | 21.2 | |||
Price To Sales Price To Sales | 3.5 | |||
Price To Book Price To Book | 2.0 | |||
EV To EBITDA EV To EBITDA | 14.3 | |||
GPM GPM% | 34.3 | 39.7 | 44.6 | 44.6 |
OPM OPM% | 17.3 | 25.4 | 28.4 | 28.4 |
NPM NPM% | 9.0 | 15.7 | 16.7 | 16.7 |
ROCE ROCE% | 18.4 | 25.0 | 23.2 | 23.2 |
ROE ROE% | 34.7 | 31.3 | 27.9 | 27.9 |
ROA ROA% | 6.2 | 12.6 | 11.7 | 11.7 |
Documents — Avience Biomedicals Ltd
Concall Transcript Summaries — Avience Biomedicals Ltd